{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-102053","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.677190+00:00","generated_at":"2026-05-31T02:29:42.713317+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio","bullets":["Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.","Dermavant shareholders also earn tiered royalty payments based on VTAMA net sales.","Transaction expected to close Q4 2024, subject to HSR and other customary conditions.","VTAMA (tapinarof) is approved for plaque psoriasis; milestone targets atopic dermatitis indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-102053","json":"https://secwatch.observer/filing/0001104659-24-102053.json","markdown":"https://secwatch.observer/filing/0001104659-24-102053.md","text":"https://secwatch.observer/filing/0001104659-24-102053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924102053/0001104659-24-102053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924102053/tm2424316d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:29:42.713317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}